2020 inventory: A-share 41 pharmaceutical companies listed, the highest open board rose 1600%

Unwittingly, the clock of history is ticking and 2020 is coming to an end.
Although, at the beginning of the outbreak, the A-share IPO market has brought some impact, but with the 2020 GEM reform and pilot registration system into the fast lane, coupled with the rise of the reputation of the board, the second half of the new issue gradually returned to normal, and this "pharmaceutical industry" IPO showed an unprecedented outbreak.
In fact, affected by market trends, this year's IPOs are not only lower in number than in previous years, but also lack of well-known companies, but in 2020 the pharmaceutical industry IPOs are much higher than the previous two years, has become the mainstay of ipos in 2020.
"new crown pneumonia", in-body diagnosis / vaccine industry IPO outbreak 2020 pharmaceutical industry new shares, medical devices and biological products accounted for the largest proportion of the two sub-sectors, in 2020 there are 11 and 12 enterprises listed, And the largest proportion of medical devices is "in-body testing", biological products accounted for the largest proportion of "vaccines", and the greatest commonality between the two is that both are related to this year's new crown outbreak, it is hard to say that perhaps choose this year's listing is to "hot spot".
What's more, among the top 10 companies in the 2020 IPO growth list (the average price/new share issue price on the opening day), Wante Bio, Kantai Bio, Kanghua Bio, Oriental Biology and New Industries accounted for half of the places and took second place.
the third-place Huluwa with a 1600% increase.
, the much-watched CRO enterprises, the whole year only "Chengdu pilot" 1 enterprise listed, not as good as Chinese medicine and raw materials enterprises each listed 3.
it seems that the cro industry as a whole fault effect is becoming more and more serious, the head of the enterprise feng shui at the same time, the bottom enterprise is suffering from the "business" source.
, coupled with the transformation of many research and development enterprises research and development / production integration enterprises, has exacerbated the situation of the industry.
HPV vaccine potential leader - Wantay biological epidemic just stabilized, Wantay biological can't wait to be listed, as a potential leader in the field of domestic HPV vaccine, not only its genetically engineered vaccine technology platform has a global leading edge, its unique "adult vaccine marketing model" and strong "production combination" effect is also one of the reasons for its success.
revenue for the first three quarters of 2020 was RMB1.599 billion, up 92.61% YoY, while non-profit margin was RMB447 million, up 273.33% YoY, far exceeding the total revenue/net profit of RMB1,184 million and RMB165 million in 2019.
there has been a huge increase in sales of "new crown test reagents", but secondary HPV vaccine revenue is also one of the factors that is not as good as ignored.
, Vantai Bio's breakthrough in the world's leading vaccine technology has forced multiple pipelines to be licensed by overseas giants, largely determining the height of its products.
and rely on the world's exclusive E. coli virus particle vaccine technology system with independent intellectual property rights at home and abroad.
has built the hepatitis E vaccine, HPV vaccine series (2 price, 4 price combined hepatitis E, 9 price and 20 price HPV vaccine, etc.), is one of the leading enterprises with a complete HPV vaccine research and development pipeline.
addition, Wante Bio has established inactivated vaccine platform, detoxifying live vaccine platform, reverse genetic vaccine platform, and is in the process of chickenpox vaccine, new chickenpox detoxifying live vaccine and other varieties of research and development.
addition to Vantai's HPV vaccine not only in technology, marketing has originality and leadership, 9 price HPV vaccine is also the fastest progress in the country, is expected to be 2-4 years ahead of competitors on the market.
from the current approved policy, only low-cost vaccine approved for high-priced HPV vaccine can be sustained infection rate as the clinical endpoint of Phase III. clinical trials, clinical cycle can save 2-3 years.
addition to Wantay Bio has been listed, the current domestic completion of low-cost HPV vaccine listing applications only Watson Bio, is expected to be approved for listing in 2021 Q4.
also said that even if Shanghai Bowei Bio and Beijing Recreation Guardian's 9-price HPV vaccine has entered Phase III clinical trials, but neither of them has a low-cost vaccine declared listed or approved for market, so Phase III. Clinical endpoint still needs to prevent precancer lesions (CIN2), the time to market will be greatly pushed back, is expected to be at least after 2027.
And, In addition to HPV, the rest of the research pipeline is equally rich, some varieties with global technology leadership, relying on "Xiamen University National Center for Infectious Disease Diagnostic Reagents and Vaccine Engineering Technology, Molecular Occinology and Molecular Diagnostics National Key Laboratory", Wanta Bio in the field of viral vaccines has a deep and leading upstream pathogen basic research, while in the downstream process has experienced E. coli expression system and virus particle assembly technology of the full set of processes.
's global leadership in viral vaccines has been endorsed and co-founded by established vaccine companies such as Sanofi Pasteur, GSK, and has even loomed a threat to them.
competitive advantages in the HPV vaccine family, chickenpox-shingles virus vaccine, new rovirus vaccine, multi-priced enterovirus vaccine, RSV inactivated vaccine are also becoming more obvious.
Anti-AI Leading Unit - Frontier Biology, known as the "Anti-Ai Leading Unit", was founded in 2013 and is an innovative biopharmaceutical company based in China, facing the world and internationally competitive, dedicated to research, development, production and sale of innovative drugs for major clinical needs that are not met.
owns an original anti-AIDS drug that has been marketed and patented in major markets around the world, and two new drugs that are in clinical trials and have been patented (or licensed).
will be listed on October 28, 2020, with an initial price of 20.5 yuan.
company's shares fell after the company surged 45.9 percent on its first day of trading.
has also become the A-share market only a few "break" enterprises.
at $18.07 at the close of trading on December 24.
2017-2019, the company lost 0.65 billion yuan, 247 million yuan and 192 million yuan, respectively, with a cumulative loss of 504 million yuan.
the first three quarters of 2020, Frontier Bio achieved revenue of only 23.22 million yuan, while net profit lost 164 million yuan.
To a large extent, the side reflects the market's "pessimistic" view of the frontier biological outlook, the main reason is that the IPO raised 2,001 million yuan of innovative biopharmaceutical companies, so far only by a new drug, and its patent rights will expire in just three years.
The new drug, which the company believes has broken the monopoly of foreign drug companies in the fight against AIDS and created China's innovative capabilities in the field, was awarded a new drug certificate by the State Drug Administration in May 2018 and will be available in China from August 2018.
sales are not as hot as the company thought.
2020, Frontier Bio achieved revenue of 953,900 yuan, down 58.08 percent from a year earlier, according to data released last year.
and the decline in performance is still in 2017-2019, the company's net profit attributable to shareholders of the parent company is -065 million yuan, -247 million yuan, -192 million yuan, to achieve three consecutive years of losses on the basis of this "anti-Ai leader" floating.
, and the trend continues. according to the
prospectine, the company expects to achieve operating income of 23.22 million yuan in the first three quarters of 2020 and net profit attributable to shareholders of the parent company of about 164 million yuan, with frontier bio-losses expected to exceed last year's in 2020.
this is why Frontier Biology uses the fifth set of listing standards for the Tablet.
this standard does not focus on the performance of IPO companies, focusing on the expected market value and technological advantages, thus allowing companies that have not yet achieved revenue to go public.
also makes investment more important to the company's future potential, and under this factor, there is no doubt that the information given by frontier organisms is far from enough.
also in China's anti-AIDS market, treatment drugs as many as nearly 30! Moreover, at least eight of these drugs are procured through the government and distributed free of charge to patients.
and for Chinese AIDS patients, free drugs are the first-line drugs that Renren does not allow.
, although frontier organisms and the former's product positioning is different, but also means that its share of the market must be limited.
, there is one more thing that is particularly noteworthy.
According to Frontier Bio prospectos, part of the capital raised from the IPO will be used for the first phase of production capacity construction in Aykonen, with an estimated annual production capacity of 2.5 million units, with production time of 2021, while in 2019, the total sales volume of Frontier Bio Aykonen will be only 262,000 units.
a serious departure from actual sales and capacity plans, is it really an optimistic judgment of frontier organisms about market space? At the same time, with the current expansion of the country's investment in aids, including reducing the standard of free AIDS treatment, expanding free AIDS drugs, to ensure the prevention and treatment of funds and drug supply.
the high cost of treatment, which costs up to 8000 yuan a month, has run counter to national policy.
the inclusion of envelistment "Evve peptide", the winning bid price is also much lower than Aykonen.
can say that, without health insurance support, Mr. Aykonen's competitive advantage is few and far between, and the ability of the company, which has negative revenue growth, to afford the health-care bureau's "soul cut."
At the same time, in addition to the impact of domestic market factors, in recent years, foreign pharmaceutical enterprises continue to accelerate the layout of China's anti-HIV self-funded drug market, some imported anti-HIV drugs in developed countries after the first approval of the market, then quickly started in China's new drug registration applications and market cultivation work, and this type of imported drugs in efficacy, safety, drug convenience, drug compliance and other aspects have certain advantages.
March 2020, a combination of Cabotegravir and Rilpivirine developed by ViiV/Jansen was approved for sale in Canada and has submitted applications for new drugs to the U.S. and European Union Food and Drug Administrations.
The combination of the two drugs as a complete treatment plan for anti-HIV treatment, by intramuscular injection once a month, and do not need to be used in combination with other antiretroviral drugs, to a greater extent to improve the patient's drug convenience and compliance.
reposed, investors are widely concerned about the risk of patent expiration, in the absence of a health-care catalog, Aykonen's economy is much lower than that of its competitors, and even if it is successfully selected in the future, the resulting lower prices could still have an impact on the earnings of Frontier Bio.
is still spreading the market, Ai Canning also has to face the import of new anti-HIV drugs into China's competition intensified.
, that is, once the drug enters China in the future, Aykonen's existing advantages will be lower.
addition, even in the current treatment, Aykonen is not the first choice.
It is understood that china AIDS diagnosis and treatment guidelines 2018 version of the tour, many experts do not recommend the use of Abbotete (i.e., Aykonen) without drug resistance testing, that is, Aykonen in addition to anti-drug resistance and other clinical irreplaceable advantages have not been recommended.
market outlook is uncertain, frontier organisms also face the risk of Aykonen's patent expiring.
after the market is not ruled out that there will be A caninen's generic drugs, thereby greatly reducing the price of Aykonen and increasing market competitiveness.
and as time progresses, the days of frontier creatures may become more and more difficult.
Summary Overall, 2020 may be a difficult year for consumption, manufacturing, etc., but for the pharmaceutical industry, at least for the biopharmaceutical industry IPO industry is a year of fish and water.
addition, from the average increase in listing, the biopharmaceutical industry with its "innovation" and "growth" to become the hottest sub-industry, and in the years to come will not diminish!